Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis.
about
Axitinib in the treatment of renal cell carcinoma: patient selection and perspectivesClinical management of regorafenib in the treatment of patients with advanced colorectal cancerEvaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinomaHypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell CarcinomaInfluence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer PatientsIncidence and risk of hypertension associated with cabozantinib in cancer patients: a systematic review and meta-analysis.Discovering Outliers of Potential Drug Toxicities Using a Large-scale Data-driven ApproachCongestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials.Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway.Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysisVascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue.A phase II study of axitinib in advanced neuroendocrine tumors.WNK signalling pathways in blood pressure regulationRisk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis.Risk of hypertension in cancer patients treated with aflibercept: a systematic review and meta-analysis.Multitargeted antiangiogenic tyrosine kinase inhibitors combined to chemotherapy in metastatic breast cancer: a systematic review and meta-analysis.Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents.Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy.Receptor tyrosine kinase inhibitors: Are they real tumor killers?Renal effects of targeted anticancer therapies.Axitinib in metastatic renal cell carcinoma.Renal Toxicities of Targeted Therapies.Targeted therapies for treatment of renal cell carcinoma: recent advances and future perspectives.Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit.Axitinib: a review in advanced renal cell carcinoma.Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.Anti-VEGF-Induced Hypertension: a Review of Pathophysiology and Treatment Options.Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs).Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma.Cancer therapeutics revisited; novel drugs targeting cell signalling pathways, genome wide association studies and other trials and tribulations.Diagnosis, Treatment, and Prevention of Cardiovascular Toxicity Related to Anti-Cancer Treatment in Clinical Practice: An Opinion Paper from the Working Group on Cardio-Oncology of the Korean Society of Echocardiography.[Side effect management of tyrosine kinase inhibitors in urology : Hypertension].Treatment-related mortality with aflibercept in cancer patients: a meta-analysis.2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
P2860
Q26751341-E108DA2E-FECD-4904-8ABF-D6B130AF73A4Q26821956-9C68B91B-15AB-47F2-88C8-BD84AD38229AQ27028048-BA607B57-05B8-4329-8893-A332BA9D2F59Q28066747-C3045A3D-D978-4A3F-87ED-F37A7BF5885BQ28080163-E813DF49-7AC8-4666-B182-F62258CD3B3BQ30250303-F01548BE-C805-4533-8501-16CD38C9CFA1Q31140868-777FD51F-094E-44AC-9F97-547257CA970AQ34554398-8AEF2951-B6A2-40EC-A49B-1002A47EF3A0Q34943606-49E86758-FB43-4A0F-9F80-6929D6C424A0Q35118673-538BB493-7CA7-4E6F-A161-B529FE3965F9Q36755620-2CBDADF2-62B1-40D9-A74A-AD991A8794AFQ37131421-9B3DFCF5-7F4F-4310-8D67-9F40B9BD7759Q37694287-7A4004DD-41C4-4275-B5CF-8E06D08740A9Q38154815-FBCCD599-FAC7-476D-94F2-413DFF70D3DCQ38184936-75B33D8D-E781-4465-86AC-6415CFB64140Q38190433-E5487E3B-F80C-403D-BA7E-20663842A465Q38196855-C1948665-7BBF-4DAA-AD4B-24A1AC3748C4Q38286128-E65374B7-DE55-4325-B9BD-E6AE4DC55019Q38365290-502DA3CE-61D4-4954-A080-7A72880AB142Q38367168-4190458D-8B3E-4AE6-8A3C-869225046618Q38439661-B7F933AC-A4B7-4BE6-B4E6-0A54B8351CB8Q38448007-46DAF4A0-56F6-46FC-A472-0ABBB7A9D0C3Q38473672-A28B262D-E3DC-4F38-83A7-2FC995DB8E67Q38501976-FB06FC62-C707-4378-914B-C3674D25C2E1Q38612808-70CDF05A-A332-4E88-B564-85ABB15A7FA1Q38657787-DB0F3508-0521-45D3-B412-225467009C35Q38757141-DE6C4A41-C44F-4487-A40C-C90EA85FDD12Q38827793-A52BB084-428B-4CD5-B87B-2AA93DD4C194Q40336236-1F323EBE-1826-48E8-A762-73B12EDDA3A7Q42091213-DAAEE703-2276-4DDB-90E2-998245292F31Q53075042-DF93C5AD-E67F-4F84-8B1D-411CB30F75BCQ54195816-00BF0DD5-5A8E-471D-A84C-0350AB95F1DCQ54386535-8A9F0266-3B80-4BC1-9956-7FAB5F226DA0Q57057499-58965D6F-4097-422B-811D-53FFE956199C
P2860
Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Incidence and risk of hyperten ...... atic review and meta-analysis.
@en
Incidence and risk of hyperten ...... atic review and meta-analysis.
@nl
type
label
Incidence and risk of hyperten ...... atic review and meta-analysis.
@en
Incidence and risk of hyperten ...... atic review and meta-analysis.
@nl
prefLabel
Incidence and risk of hyperten ...... atic review and meta-analysis.
@en
Incidence and risk of hyperten ...... atic review and meta-analysis.
@nl
P2093
P2860
P921
P356
P1476
Incidence and risk of hyperten ...... atic review and meta-analysis.
@en
P2093
P2860
P304
P356
10.1111/BCP.12149
P407
P50
P577
2013-09-01T00:00:00Z